论文部分内容阅读
目的 :减少中晚期胃、结直肠恶性肿瘤术后腹腔内复发和肝脏转移率。方法 :将 14 3例患者随机分成腹腔化疗组 (观察组 ) 70例 ,静脉化疗组 (对照组 ) 73例。结果 :观察组与其对照组相比 ,术后腹腔内复发例数 4 /18,χ2 =9 5 8,P <0 0 0 5 ,肝转移例数 1/10 ,χ2 =7 5 8,P <0 0 0 5 ,近期死亡例数 2 /10 ,χ2 =16 5 3 ,P <0 0 0 5 ,三年以上存活 2 1/11,χ2 =4 5 9,P <0 0 5。结论 :对该类患者术后采用 5 -Fu +MMC腹腔化疗在减少腹腔内复发和肝脏转移方面 ,近期优于静脉化疗。
Objective : To reduce the postoperative intraperitoneal recurrence and hepatic metastasis rate in patients with advanced gastric and colorectal malignancies. Methods: Four hundred and thirty-three patients were randomly divided into 70 cases of intraperitoneal chemotherapy group (observation group) and 73 cases of intravenous chemotherapy group (control group). RESULTS: Compared with the control group, the observation group had 4/18 intra-abdominal recurrences, χ 2 =95.58, P <0 0 05, liver metastases 1/10, and χ 2 =7 5 8,P < 0 0 0 5 , the number of recent deaths was 2/10, χ 2 =16 5 3, P <0 0 05, more than three years surviving 2 1/11, χ 2 =4 5 9, P <0 0 5. Conclusion : The postoperative 5-Fu+MMC intraperitoneal chemotherapy for this type of patients is superior to intravenous chemotherapy in reducing intraperitoneal recurrence and liver metastasis.